Navigation Links
PTC Therapeutics to Present at Credit Suisse Annual Health Care Conference
Date:11/5/2013

SOUTH PLAINFIELD, N.J., Nov. 5, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 2013 Credit Suisse Annual Health Care Conference on Tuesday, November 12 at 4:30 pm ET.

(Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO )

The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com. The presentation will be archived for two weeks following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.

About PTC Therapeutics, Inc.

PTC is biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and form the basis for collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website www.ptcbio.com

Forward Looking Statements:

Any statements in this press release about future expectations, plans and prospects for PTC, the development of and potential market for our product candidates,  and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan" "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by these forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory approvals, our scientific approach and general development progress, the availability or commercial potential of our product candidates and other factors discussed in the "Risk Factors" in the most recent Quarterly Report, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views only as of the date of this release. We anticipate that subsequent events and developments will cause the our views to change. However, while PTC may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing PTC's views as of any date subsequent to the date of this press release.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alba Therapeutics Appoints Wendy Perrow Chief Executive Officer
2. Sorrento Therapeutics Enters into Antibody and Vaccine Development Alliance for the Prevention and Treatment of Obesity
3. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
4. Mast Therapeutics Reports Third Quarter 2013 Financial Results
5. Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
6. Echo Therapeutics Schedules Third Quarter 2013 Financial Results for Thursday, November 7, 2013
7. G1 Therapeutics to Present at Southeast BIO Investor & Partnering Forum
8. Cell Therapeutics Reports Third Quarter 2013 Financial Results
9. Sorrento Therapeutics Announces Closing of Public Offering of Common Stock
10. Abide Therapeutics Appoints Dr. Gary ONeill as Vice President of Biology
11. Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical ... independent supplier of medical equipment, supplies, drugs, vaccines, and ... has entered into an agreement to acquire Vantage Medical ... based in Holtsville, New York . ... in supplying new and emerging medical practices, will operate ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Lori R. Somekh, founder of the Law Office ... of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office ... forum to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
Breaking Medicine News(10 mins):